Some boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.
By Jason Mast
May 11, 2026
Jason Mast
jason.mast@statnews.com
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
After an apparent cure, a gene editing company struggles to repeat the magic
In a milestone for ALS, a treatment helps some patients improve
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
Boy’s brain tumor tied to gene therapy
A Zillow-like marketplace for abandoned gene therapies goes live
Doctors have linked a boy's tumor to a gene therapy, but say the rare risks need to be weighed against the profound benefits such…
“We’re still very much in the early stages,” a gene therapy expert said. “But every day, he’s showing us signs that he’s growing…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it…
Grace Science CEO Matt Wilsey says FDA demands could kill its gene therapy for the rare and fatal NGLY1 deficiency by September…
